A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)

Exclusion Criteria

• •Part 1: Positive urine test for drugs of abuse
• •Part 1: History of exposure or active viral infection of Hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
• •Part 1: Cardiac disease including hypertension or hypotension
• •Part 1: Lower extremity edema
• •Part 1: Any clinically relevant history of systemic disease
• •Part 1: History of breast cancer
• •Part 1: Chronic corticosteroid use
• •Part 1: Receipt of IV antibiotics within 7 days prior to enrollment
• •Part 2: Concurrent malignancy requiring therapy that may interfere with pharmacokinetic investigations, or history of other malignancy within 5 years prior to Screening
• •Part 2: Significant cumulative exposure to anthracyclines
• •Part 2: Serious cardiac disease including uncontrolled hypertension
• •Part 2: Poor hematologic, renal, or hepatic function
• •Part 2: Pregnant or lactating women
• •Part 2: History of exposure or active viral infection of Hepatitis B, hepatitis C, or HIV
• •Part 2: Chronic corticosteroid use
• •Part 2: Receipt of IV antibiotics within 7 days prior to enrollment